Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024

Key Takeaway: SI-BONE, Inc. (Nasdaq: SIBN) announced it will participate in the 2024 BofA Securities Healthcare Conference in Las Vegas on May 14, 2024. Management will host a fireside chat at 2:20 p.m. Eastern Time. Investors can register to listen to the live audio webcast, which will also be archived for 90 days following the event. The company is a leader in surgical treatments for musculoskeletal disorders and has supported extensive surgical procedures, reinforced by significant clinical evidence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in the 2024 BofA Securities Healthcare Conference highlights the company's visibility and engagement with investors.
  • SI-BONE's history of supporting over 3,600 surgeons and performing over 95,000 procedures showcases their established presence in the market.
  • The company has a robust body of clinical evidence with multiple randomized controlled trials supporting their technologies.

Full Press Release Details

SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 14, at 2:20 p.m. Eastern Time / 11:20 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2024/idwLc6ml.cfm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

When is SI-BONE participating in the 2024 BofA Healthcare Conference?

SI-BONE will participate on May 14, 2024, at 2:20 p.m. ET.

How can investors listen to the SI-BONE conference call?

Investors can register for the conference call at the BofA link provided.

What is SI-BONE's expertise in medical technology?

SI-BONE specializes in surgical treatments for musculoskeletal disorders.

What types of procedures has SI-BONE conducted?

SI-BONE has supported over 95,000 sacropelvic procedures since 2009.

Where can I find more information about SI-BONE products?

Additional information is available on SI-BONE's official website.

Last updated: Apr 29, 2024